{"name":"Ocular Therapeutix","slug":"ocular","ticker":"OCUL","exchange":"NASDAQ","domain":"ocutx.com","description":"Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is hea","hq":"Bedford, MA","founded":0,"employees":"325","ceo":"Antony Mattessich","sector":"Ophthalmology","stockPrice":9.33,"stockChange":0.09,"stockChangePercent":0.97,"marketCap":"$2.0B","metrics":{"revenue":52038000,"revenueGrowth":0.8,"grossMargin":0,"rdSpend":197096000,"netIncome":-265939000,"cash":666699008,"dividendYield":0,"peRatio":-6.1,"fiscalYear":"FY2018"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"DEXTENZA patent cliff ($100M at risk)","drug":"DEXTENZA","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"OTX-TKI","genericName":"OTX-TKI","slug":"otx-tki","indication":"Dry eye disease","status":"phase_3"},{"name":"Ophthalmic Insert","genericName":"Ophthalmic Insert","slug":"ophthalmic-insert","indication":"Dry eye disease","status":"phase_3"},{"name":"Punctum Plug","genericName":"Punctum Plug","slug":"punctum-plug","indication":"Treatment of dry eye disease","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"OTX-TKI (axitinib implant)","genericName":"OTX-TKI (axitinib implant)","slug":"otx-tki-axitinib-implant","indication":"Metastatic renal cell carcinoma","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Dexamethasone, 0.4mg","genericName":"Dexamethasone, 0.4mg","slug":"dexamethasone-0-4mg","indication":"Other","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Dextenza Ophthalmic Insert","genericName":"Dextenza Ophthalmic Insert","slug":"dextenza-ophthalmic-insert","indication":"Post-operative inflammation and pain following ocular surgery","status":"phase_3"}]}],"pipeline":[{"name":"OTX-TKI","genericName":"OTX-TKI","slug":"otx-tki","phase":"phase_3","mechanism":"OTX-TKI is a tyrosine kinase inhibitor designed for topical ocular delivery to treat eye surface diseases.","indications":["Dry eye disease","Ocular surface inflammation"],"catalyst":""},{"name":"OTX-TKI (axitinib implant)","genericName":"OTX-TKI (axitinib implant)","slug":"otx-tki-axitinib-implant","phase":"phase_3","mechanism":"OTX-TKI (axitinib implant) is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors.","indications":["Metastatic renal cell carcinoma"],"catalyst":""},{"name":"Ophthalmic Insert","genericName":"Ophthalmic Insert","slug":"ophthalmic-insert","phase":"phase_3","mechanism":"An ophthalmic insert that delivers medication directly to the eye to treat ocular surface disease and inflammation.","indications":["Dry eye disease","Ocular surface disease"],"catalyst":""},{"name":"Dexamethasone, 0.4mg","genericName":"Dexamethasone, 0.4mg","slug":"dexamethasone-0-4mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Dextenza Ophthalmic Insert","genericName":"Dextenza Ophthalmic Insert","slug":"dextenza-ophthalmic-insert","phase":"phase_3","mechanism":"Dextenza is a corticosteroid-eluting ophthalmic insert that delivers dexamethasone directly to ocular tissues to reduce inflammation and pain following eye surgery.","indications":["Post-operative inflammation and pain following ocular surgery","Corneal refractive surgery pain and inflammation"],"catalyst":""},{"name":"Punctum Plug","genericName":"Punctum Plug","slug":"punctum-plug","phase":"phase_3","mechanism":"Punctum Plug is a biodegradable collagen shield used to treat punctal occlusion.","indications":["Treatment of dry eye disease"],"catalyst":""}],"recentEvents":[{"date":"2023-02-28","type":"earnings","headline":"Ocular Therapeutix Reports Fourth Quarter and Full Year 2022 Financial Results","summary":"Ocular Therapeutix reported its financial results for the fourth quarter and full year 2022, with net sales of $13.1 million for the quarter and $44.6 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2022-11-14","type":"deal","headline":"Ocular Therapeutix Announces $25 Million Private Placement Financing","summary":"Ocular Therapeutix announced a private placement financing of $25 million, which will be used to support the company's product development and commercialization efforts.","drugName":"","sentiment":"positive"},{"date":"2022-08-09","type":"regulatory","headline":"FDA Approves DEXTENZA for the Treatment of Post-Surgical Ocular Inflammation and Pain","summary":"The FDA approved DEXTENZA for the treatment of post-surgical ocular inflammation and pain, expanding the product's indication to include this condition.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-05","type":"trial","source":"simplywall.st","summary":"Will Ocular Therapeutix’s (OCUL) AXPAXLI Data Spotlight Redefine Its Retinal Competitive Positioning? - simplywall.st","headline":"Will Ocular Therapeutix’s (OCUL) AXPAXLI Data Spotlight Redefine Its Retinal Competitive Positioning?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-03","type":"trial","source":"simplywall.st","summary":"Assessing Ocular Therapeutix (OCUL) Valuation As Axpaxli Phase 3 SOL-1 Data Draws Fresh Investor Focus - simplywall.st","headline":"Assessing Ocular Therapeutix (OCUL) Valuation As Axpaxli Phase 3 SOL-1 Data Draws Fresh Investor Focus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQdDAzdjlTUGNlZlhYTTd3ZHdfWmNLZWRuQnlBMzhwUEZFajlIVTVzaHRacTY2Zi1RZndrRFYyOC13ZUl6MmVpR1UzdG52ZHNQT2tjZ1VzWnVkMVdZa3VCNEJ5dzBSdXI3eGIzcXRpSHZPNzRvWWo2WXE5SW5uWTVCTUFNckpUQnIwZGY5V0xjZGVlc0wtQ0pGN3dJTG80S0dUUXBYU1EyOXd1YlB3SjA0ZlFWMVd0TUdSazFoclVfRXZ2UGp3Vmw0?oc=5","date":"2026-03-22","type":"pipeline","source":"Reuters","summary":"EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug - Reuters","headline":"EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxONS1IbXZkM1lXWko0SHdCVFdDem83ci14eHdUX2xVRXVLOThEQmZLTHJ5aFRUTk5jUmdHdjQ5UUhUSzdlY1JPei1KdEtXMHlkU0NCVVVLQ25XNVFXdXNYZmx1eEwwNG1uUmExc2VVeGdMT0tzR2RZejhYQ1luZGZnQTNONVJZUVJVRUZKSFN2ZzdVSU0?oc=5","date":"2026-03-12","type":"earnings","source":"Yahoo Finance","summary":"Pharmaceuticals Stocks Q4 Highlights: Ocular Therapeutix (NASDAQ:OCUL) - Yahoo Finance","headline":"Pharmaceuticals Stocks Q4 Highlights: Ocular Therapeutix (NASDAQ:OCUL)","sentiment":"neutral"},{"date":"2026-02-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOMW9LX2dUWTgzSmE5dGNiYnpwRmNtclpjcGJmQ1haSy1MNHJySmVDTFYydjlWRWZIN2RuRHNwb1owV1NDcVpQZzNrZGFXYUg5WnJBdWFIU0pNOE05SFB2bTZlaTJ6S0dWZ2N4QlE3S2Fub1l3ZEhRRE40bHlpTjV5Sk10Y2Q3LW9DbF9feFNyU0cwTm5GVGZsWGZvXzVlczNPLUZ4V1lSSFBFbU1L?oc=5","date":"2026-02-18","type":"trial","source":"The Pharma Letter","summary":"Positive billing but Ocular’s Axpaxli data disappoints investors - The Pharma Letter","headline":"Positive billing but Ocular’s Axpaxli data disappoints investors","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPeG5pb3Zod3ZVVUx3dGdGWTNUMXZtNWMwR1RFVXYzRDFCbGwzNUswWEc5MVFmeUhzZmh6cUQyMHNZaWdrNUhHbkhCM0RwODlPTzZtOFpueUdUVmpzOTA3SzR4ZmVkRUE0MGlqcWRiMWp0YnIyTmZBNTJlMU5XZVUteFMzZVh0N3NqOG94UXN1dUViQ3RxTU5nWFo2dnVFTloxbnJNaGVDRFQ1WG1qQWc?oc=5","date":"2026-02-17","type":"regulatory","source":"MedCity News","summary":"Ocular Therapeutix Eyes FDA Filing After Wet AMD Drug Tops Regeneron’s Eylea in Phase 3 Test - MedCity News","headline":"Ocular Therapeutix Eyes FDA Filing After Wet AMD Drug Tops Regeneron’s Eylea in Phase 3 Test","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxNVnkwelBYSVpJN21wZS1sSVdvTXV0R1ZCMWk5aUdreHRzOV9XOEhHMC1yUUNiRjJZSkpIZVRGWS1tb0EwUG1vWVRCWlh5a0thdnBhaUN2ZlNXWklFWmprYWxfbndPMFk3THJKV1M0WXlIWHY2bWhyNlRfLV90TEFvZHVTRURzV1NQWHRLWEM1Tkg0WnB2TksyRmNLNjd1TVFGS2dfUUV6MlRqOVNiVjdNdzhxby1JVzAyWXl1ODNrVmdRa05OajNkbDFLdkswM0FpaS05UEJyejY1SjNYNmdIMGk5aGpudEJsR1JMS3o4NkpmeUFJT3FlbHc0TUY?oc=5","date":"2026-02-16","type":"trial","source":"FinancialContent","summary":"Sanofi Tightens Grip on Ocular Therapeutix with Revised Bid as Pivotal SOL-1 Trial Results Loom - FinancialContent","headline":"Sanofi Tightens Grip on Ocular Therapeutix with Revised Bid as Pivotal SOL-1 Trial Results Loom","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQcjNicllkY3hSaEdmc05nN0Rqa2tHZFV5X3VJX3d4bENNeWhHVFJNOG5heFFlMFBESDJsRHRTazJudlVkeUpORVQyYVhjRGhIWFlzUjFobUY0SmFHU2l2Skd5RzF5aGNQOXFjTUNENTN5YVJuMlZqVDhFTFkxbGlPMUNtYWRkbEE?oc=5","date":"2026-02-05","type":"trial","source":"statnews.com","summary":"A rival goes after Ocular Therapeutix on eve of pivotal readout on eye treatment - statnews.com","headline":"A rival goes after Ocular Therapeutix on eve of pivotal readout on eye treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPcGRVemtaSWRYcFF2dlJCODZyWVlURWFYZ1o0WmtjQjRrazk3OGIyOHZUMDVqdGRqRF9oclNYNUtVT0NBbTFHSEJSTFI0ZkZsQkM1YkJQSWxrcENFS3Fyam52TWkyMG9OUjllV1B5UVR1eVFOcUhyVEJCWFJkYlUtZk1obVlKWHBm?oc=5","date":"2026-01-26","type":"earnings","source":"Yahoo Finance","summary":"A Look Back at Pharmaceuticals Stocks’ Q3 Earnings: Ocular Therapeutix (NASDAQ:OCUL) Vs The Rest Of The Pack - Yahoo Finance","headline":"A Look Back at Pharmaceuticals Stocks’ Q3 Earnings: Ocular Therapeutix (NASDAQ:OCUL) Vs The Rest Of The Pack","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxORXJ3TUN1SWJRUkJYNHNPX2dUQmZodDl6b3lCVGFsRWdyeWVvSUJ5MlRON3o4ZmJMcC1VRThVQjBmWmxDSGdRRGF4amo0cVdNdE5kRlRidjZzUjYtdVlSZ1p2czZOemJHd1ZyNnVBYzdQZ3JjRnJiQkFFY3p3ckRtTjlMRXBIemNudkxtcXJMYjREVm4tcU5n?oc=5","date":"2026-01-16","type":"pipeline","source":"BioSpace","summary":"Speculation of Sanofi Takeover Sends Ocular’s Stock Soaring - BioSpace","headline":"Speculation of Sanofi Takeover Sends Ocular’s Stock Soaring","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPYlJMdEVrS1NpOV9aa3NDUnU5RVRzampwWkpLbmpmSjYzV0xfT2JKVE1jMzA4dHU2SVNfeWd3MmQyT3lQeE1DT0tKcmRhdWt0aHQ3Q1FJYW1wdFdLZWxNRnBjN1c2dXJvUDcxUDYxSVVDNXl0Y000cGZyRzlLUkg0QlpjUzNCNFJFbWhV?oc=5","date":"2026-01-15","type":"pipeline","source":"Investor's Business Daily","summary":"Ocular Launches, And Then Yo-Yoes, On Rumors Sanofi Is Preparing A Bigger Bid - Investor's Business Daily","headline":"Ocular Launches, And Then Yo-Yoes, On Rumors Sanofi Is Preparing A Bigger Bid - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQUXRPbnBON3J1Y3JBUVBKRHRKb3llTHl5ZkEzeHBHX3duMVN2Z0ZuNnBWbXBqMHZ6UWFyQTk5YW40aUIwQ29RQUNwQ2w3R0pORjgwdjJOZWxockxsU1FING1aWGRZQm91QVpwVDkzX0g1MXZJUl9rWVptQ0VPWjZTYjRiaDhGUQ?oc=5","date":"2026-01-15","type":"deal","source":"Seeking Alpha","summary":"Ocular surges on report of Sanofi buyout bid - Seeking Alpha","headline":"Ocular surges on report of Sanofi buyout bid","sentiment":"neutral"}],"patents":[{"drugName":"DEXTENZA","drugSlug":"dexamethasone","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":100000000}],"drugCount":6,"phaseCounts":{"phase_3":5,"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Alcon","Bausch Health","Regeneron"],"therapeuticFocus":["Glaucoma","Dry Eye"],"financials":{"source":"sec_edgar+yahoo","revenue":1990000,"revenuePeriod":"2018-12-31","revenueHistory":[{"value":1990000,"period":"2018-12-31"},{"value":504000,"period":"2018-12-31"},{"value":498000,"period":"2018-09-30"},{"value":648000,"period":"2018-06-30"},{"value":340000,"period":"2018-03-31"}],"grossProfit":45377000,"grossProfitHistory":[{"period":"2025-12-31","value":45377000},{"period":"2024-12-31","value":58097000},{"period":"2023-12-31","value":53162000},{"period":"2022-12-31","value":46954000}],"rdSpend":197096000,"rdSpendHistory":[{"period":"2025-12-31","value":197096000},{"period":"2024-12-31","value":127635000},{"period":"2023-12-31","value":61055000},{"period":"2022-12-31","value":53462000}],"sgaSpend":118298000,"operatingIncome":-270017000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-270017000},{"period":"2024-12-31","value":-171781000},{"period":"2023-12-31","value":-82382000},{"period":"2022-12-31","value":-78654000}],"netIncome":-265939000,"netIncomeHistory":[{"period":"2025-12-31","value":-265939000},{"period":"2024-12-31","value":-193506000},{"period":"2023-12-31","value":-80736000},{"period":"2022-12-31","value":-71038000}],"eps":-1.42,"epsHistory":[{"period":"2025-12-31","value":-1.42},{"period":"2024-12-31","value":-1.22},{"period":"2023-12-31","value":-1.02},{"period":"2022-12-31","value":-0.97}],"cash":737060000,"cashHistory":[{"period":"2025-12-31","value":737060000},{"period":"2024-12-31","value":392102000},{"period":"2023-12-31","value":195807000},{"period":"2022-12-31","value":102300000}],"totalAssets":808057000,"totalLiabilities":153747000,"totalDebt":76968000,"equity":654310000,"operatingCashflow":-204883000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-204883000},{"period":"2024-12-31","value":-134677000},{"period":"2023-12-31","value":-70234000},{"period":"2022-12-31","value":-59603000}],"capex":-12010000,"capexHistory":[{"period":"2025-12-31","value":-12010000},{"period":"2024-12-31","value":-1288000},{"period":"2023-12-31","value":-6087000},{"period":"2022-12-31","value":-3715000}],"freeCashflow":-216893000,"dividendsPaid":null,"buybacks":null,"employees":325,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":30616000,"ebit":-61822000,"ebitda":-60575000,"period":"2025-12-31","revenue":13250000,"epsBasic":-0.29,"netIncome":-64654000,"rdExpense":50800000,"epsDiluted":-0.29,"grossProfit":11656000,"operatingIncome":-69760000},{"sga":29110000,"ebit":-66416000,"ebitda":-65347000,"period":"2025-09-30","revenue":14544000,"epsBasic":-0.38,"netIncome":-69418000,"rdExpense":52358000,"epsDiluted":-0.38,"grossProfit":12770000,"operatingIncome":-68698000},{"sga":28075000,"ebit":-64798000,"ebitda":-63772000,"period":"2025-06-30","revenue":13459000,"epsBasic":-0.39,"netIncome":-67814000,"rdExpense":51081000,"epsDiluted":-0.39,"grossProfit":11515000,"operatingIncome":-67641000},{"sga":30496000,"ebit":-61069000,"ebitda":-60088000,"period":"2025-03-31","revenue":10698000,"epsBasic":-0.38,"netIncome":-64053000,"rdExpense":42857000,"epsDiluted":-0.38,"grossProfit":9436000,"operatingIncome":-63917000},{"sga":25439000,"ebit":-45282000,"ebitda":-44331000,"period":"2024-12-31","revenue":17082000,"epsBasic":-0.29,"netIncome":-48388000,"rdExpense":40989000,"epsDiluted":-0.29,"grossProfit":15852000,"operatingIncome":-50576000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":9.33,"previousClose":9.24,"fiftyTwoWeekHigh":16.44,"fiftyTwoWeekLow":6.23,"fiftyTwoWeekRange":"6.23 - 16.44","fiftyDayAverage":9.05,"twoHundredDayAverage":10.96,"beta":0.93,"enterpriseValue":1435956736,"forwardPE":-6.1,"priceToBook":3.08,"priceToSales":39.26,"enterpriseToRevenue":27.59,"enterpriseToEbitda":-4.87,"pegRatio":0,"ebitda":-294815008,"ebitdaMargin":0,"freeCashflow":-148761504,"operatingCashflow":-226204992,"totalDebt":79462000,"debtToEquity":13.7,"currentRatio":14.81,"returnOnAssets":-32.9,"returnOnEquity":-68.6,"analystRating":"1.4 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":11,"targetMeanPrice":26,"targetHighPrice":34,"targetLowPrice":18,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.9,"institutionHeldPercent":91.6,"sharesOutstanding":218960358,"floatShares":216604345,"sharesShort":24793045,"shortRatio":7.49,"shortPercentOfFloat":11.3,"epsTrailing":-1.44,"epsForward":-1.53,"revenuePerShare":0.26,"bookValue":3.03,"officers":[{"age":61,"name":"Dr. Pravin U. Dugel M.D.","title":"Executive Chairman, President & CEO"},{"age":51,"name":"Dr. Namrata  Saroj","title":"Chief Business Officer"},{"age":null,"name":"Mr. Chad  Clatterbaugh","title":"Chief of Staff"},{"age":null,"name":"Mr. Art  Ciociola","title":"Chief Regulatory & Quality Officer"},{"age":66,"name":"Mr. David W. Robinson","title":"Global Chief Commercial Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.ocutx.com","phone":"781 357 4000"}}